A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...

A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.

An update from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) is now available. Shanghai Henlius Biotech, Inc. announced that its New Drug ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

Indoco Remedies receives US FDA final approval for rivaroxaban tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg: Our Bureau, Mumbai Wednesday, August 13, 2025, 13:45 Hrs [IST] Indoco R ...

Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Dr. Aaron Gerds explained when treatment with rusfertide will become accessible for patients with a myeloproliferative neoplasm like polycythemia vera.

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and ...

As agentic AI advances, it will impact patient-facing healthcare delivery models, while new questions around the ...

Zydus Lifesciences exceeded expectations in the June quarter with a 6% revenue growth to ₹6,573 crore and a net profit of ...

Researchers from Simon Fraser University have unveiled an artificial intelligence framework that could transform drug development and accelerate the ...